894 related articles for article (PubMed ID: 16731298)
1. Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC).
Pizzarelli F; David S; Sala P; Icardi A; Casani A
Am J Kidney Dis; 2006 Jun; 47(6):1027-35. PubMed ID: 16731298
[TBL] [Abstract][Full Text] [Related]
2. Haemoglobin response to subcutaneous versus intravenous epoetin alfa administration in iron-replete haemodialysis patients.
Leikis MJ; Kent AB; Becker GJ; McMahon LP
Nephrology (Carlton); 2004 Jun; 9(3):153-60. PubMed ID: 15189176
[TBL] [Abstract][Full Text] [Related]
3. Interpatient variation in response to subcutaneous versus intravenous low dose erythropoietin.
Barclay PG; Fischer ER; Harris DC
Clin Nephrol; 1993 Nov; 40(5):277-80. PubMed ID: 8281716
[TBL] [Abstract][Full Text] [Related]
4. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
Attallah N; Osman-Malik Y; Frinak S; Besarab A
Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
[TBL] [Abstract][Full Text] [Related]
6. [Guidelines for the treatment of anemia in chronic renal failure].
Triolo G;
G Ital Nefrol; 2003; 20 Suppl 24():S61-82. PubMed ID: 14666504
[TBL] [Abstract][Full Text] [Related]
7. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U;
Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
[TBL] [Abstract][Full Text] [Related]
8. Erythropoietin requirements: a comparative multicenter study between peritoneal dialysis and hemodialysis.
Coronel F; Herrero JA; Montenegro J; Fernandez C; Gandara A; Conesa J; Rivera MT; Torrente J; Portolés J; Gomez-Martino JR
J Nephrol; 2003; 16(5):697-702. PubMed ID: 14733416
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
Smith WB; Dowell JA; Pratt RD
Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
[TBL] [Abstract][Full Text] [Related]
10. Subcutaneous epoetin-alpha every one, two, and three weeks in renal anemia.
Piccoli A; Malagoli A; Komninos G; Pastori G
J Nephrol; 2002; 15(5):565-74. PubMed ID: 12455725
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial.
Klinger M; Arias M; Vargemezis V; Besarab A; Sulowicz W; Gerntholtz T; Ciechanowski K; Dougherty FC; Beyer U
Am J Kidney Dis; 2007 Dec; 50(6):989-1000. PubMed ID: 18037099
[TBL] [Abstract][Full Text] [Related]
12. A comparison between once-weekly and twice- or thrice-weekly subcutaneous injection of epoetin alfa: results from a randomized controlled multicentre study.
Lee YK; Kim SG; Seo JW; Oh JE; Yoon JW; Koo JR; Kim HJ; Noh JW
Nephrol Dial Transplant; 2008 Oct; 23(10):3240-6. PubMed ID: 18469158
[TBL] [Abstract][Full Text] [Related]
13. C.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks.
Spinowitz B; Coyne DW; Lok CE; Fraticelli M; Azer M; Dalal S; Villa G; Rosansky S; Adamis H; Beyer U;
Am J Nephrol; 2008; 28(2):280-9. PubMed ID: 18004064
[TBL] [Abstract][Full Text] [Related]
14. Results of the European Survey on Anaemia Management 2003 (ESAM 2003): current status of anaemia management in dialysis patients, factors affecting epoetin dosage and changes in anaemia management over the last 5 years.
Jacobs C; Frei D; Perkins AC
Nephrol Dial Transplant; 2005 May; 20 Suppl 3():iii3-24. PubMed ID: 15824128
[TBL] [Abstract][Full Text] [Related]
15. Conversion from subcutaneous to intravenous erythropoietin in a hemodialysis population.
Vercaigne LM; Collins DM; Penner SB
J Clin Pharmacol; 2005 Aug; 45(8):895-900. PubMed ID: 16027399
[TBL] [Abstract][Full Text] [Related]
16. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
Li H; Wang SX
Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia.
Krivoshiev S; Wizemann V; Czekalski S; Schiller A; Pljesa S; Wolf-Pflugmann M; Siebert-Weigel M; Koytchev R; Bronn A;
Adv Ther; 2010 Feb; 27(2):105-17. PubMed ID: 20369312
[TBL] [Abstract][Full Text] [Related]
18. Erythropoietin dose requirements when converting from subcutaneous to intravenous administration among patients on hemodialysis.
Moist LM; Muirhead N; Wazny LD; Gallo KL; Heidenheim AP; House AA
Ann Pharmacother; 2006 Feb; 40(2):198-203. PubMed ID: 16449549
[TBL] [Abstract][Full Text] [Related]
19. Switching from subcutaneous to intravenous erythropoietin alpha in haemodialysis patients requires a major dose increase.
Galliford JW; Malasana R; Farrington K
Nephrol Dial Transplant; 2005 Sep; 20(9):1956-62. PubMed ID: 15930017
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis.
Haag-Weber M; Vetter A; Thyroff-Friesinger U;
Clin Nephrol; 2009 Nov; 72(5):380-90. PubMed ID: 19863881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
